Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mitoglitazone
- Development stage
- Phase 2
- Lead developer
- Metabolic Solutions Development Company
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mitoglitazone (MSDC-0160) is an investigational, once-daily oral insulin sensitizer developed by Metabolic Solutions Development Company. It is the prototype of a new class of therapeutic agents called mTOT (mitochondrial Target of Thiazolidinediones) modulators. Mitoglitazone is a PPAR-sparing thiazolidinedione (TZD) that improves insulin sensitivity and lowers glucose levels by selectively modulating mitochondrial metabolism and nutrient-sensing pathways, specifically targeting the mitochondrial pyruvate carrier (MPC) complex. Unlike traditional TZDs, it does not directly activate nuclear transcription factors such as PPAR-gamma, which is intended to reduce side effects like weight gain and edema. It has been evaluated in Phase 2 clinical trials for type 2 diabetes mellitus and Alzheimer's disease.
- Brand names
- Mitoglitazone
- Other names
- mitoglitazoneMSDC-0160MSDC0160MSDC 0160
02
Targets
MPC (Mitochondrial pyruvate carrier)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on Mitoglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitoglitazone.